Phase I Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin), a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Advanced Malignant Melanoma.
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2011
At a glance
- Drugs Etaracizumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- 28 Jan 2008 Status changed from in progress to completed.
- 26 Aug 2005 New trial record.